论文信息 - Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. - 字舞流文

Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer.

V. Zagonel | F. Loupakis | A. Falcone | S. Lonardi | C. Cremolini | F. Bergamo | M. Schirripa

[1] S. Kumar,et al. KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model. , 2014, Gastrointestinal cancer research : GCR.

[2] C. Bokemeyer,et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3] A. Bardelli,et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. , 2010, JAMA.